Chemotherapy-Free Frontline Therapy in Indolent B-Cell Non-Hodgkin Lymphoma: Insights from Mosunetuzumab and Response-Adapted Polatuzumab Vedotin with Obinutuzumab

Highlight

• This chemotherapy-free regimen in untreated indolent B-cell NHL achieves an 86% complete response rate by PET-CT.
• Frontline single-agent mosunetuzumab yields a 71% complete response rate, while response-adapted polatuzumab vedotin plus obinutuzumab salvages non-CR patients effectively.
• The 2-year progression-free survival reaches 89%, with minimal high-grade toxicity and manageable cytokine release syndrome limited to grade 1.
• This approach offers a promising personalized treatment template balancing efficacy and safety, potentially transforming frontline management of follicular and marginal zone lymphoma.